Noxopharm Ltd (NOX) - Cash Flow Conversion Efficiency

Latest as of December 2025: 2.404x

Based on the latest financial reports, Noxopharm Ltd (NOX) has a cash flow conversion efficiency ratio of 2.404x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.71 Million ≈ $-1.92 Million USD) by net assets (AU$-1.13 Million ≈ $-797.75K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NOX net asset quality index to measure how much of total assets are equity-financed.

Noxopharm Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Noxopharm Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Noxopharm Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Noxopharm Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Noxopharm Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Eastern Metals Ltd AU:EMS	-0.397x
Liberty TripAdvisor Holdings, Inc NASDAQ:LTRPA	-0.012x
Eterindo Wahanatama Tbk JK:ETWA	0.003x
Mongolia Growth Group Ltd. V:YAK	0.080x
London City Equities Ltd AU:LCE	-0.198x
Puncak Niaga Holdings Bhd KLSE:6807	0.051x
Riley Gold Corp V:RLYG	-0.026x
Alpcot Holding AB Series B ST:ALPCOT-B	-0.037x

Annual Cash Flow Conversion Efficiency for Noxopharm Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Noxopharm Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Noxopharm Ltd (NOX) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$689.96K ≈ $488.19K	AU$-5.82 Million ≈ $-4.12 Million	-8.442x	-6679.01%
2024-06-30	AU$5.50 Million ≈ $3.89 Million	AU$-684.31K ≈ $-484.19K	-0.125x	+89.68%
2023-06-30	AU$9.07 Million ≈ $6.42 Million	AU$-10.95 Million ≈ $-7.75 Million	-1.206x	-111.87%
2022-06-30	AU$24.12 Million ≈ $17.06 Million	AU$-13.73 Million ≈ $-9.72 Million	-0.569x	-162.35%
2021-06-30	AU$40.78 Million ≈ $28.85 Million	AU$-8.85 Million ≈ $-6.26 Million	-0.217x	+74.91%
2020-06-30	AU$12.87 Million ≈ $9.11 Million	AU$-11.14 Million ≈ $-7.88 Million	-0.865x	-112.84%
2019-06-30	AU$-1.45 Million ≈ $-1.03 Million	AU$-9.78 Million ≈ $-6.92 Million	6.740x	+853.61%
2018-06-30	AU$10.15 Million ≈ $7.18 Million	AU$-9.08 Million ≈ $-6.42 Million	-0.894x	+24.37%
2017-06-30	AU$2.47 Million ≈ $1.75 Million	AU$-2.92 Million ≈ $-2.06 Million	-1.183x	-1179.11%
2016-06-30	AU$5.95 Million ≈ $4.21 Million	AU$-549.72K ≈ $-388.96K	-0.092x	--

About Noxopharm Ltd

AU:NOX Australia Biotechnology

Market Cap

$19.13 Million

AU$27.04 Million AUD

Market Cap Rank

#25262 Global

#1067 in Australia

Share Price

AU$0.09

Change (1 day)

+11.39%

52-Week Range

AU$0.06 - AU$0.13

All Time High

AU$1.58